Strides Pharma Valuation Multiples

Strides Pharma Overview

About Strides Pharma

Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.

Founded

1990

HQ

Employees

2.8K

Website

strides.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $524M

EBITDA: $101M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Strides Pharma Financials

Strides Pharma reported last 12-month revenue of $524M and EBITDA of $101M.

In the same LTM period, Strides Pharma generated $101M in EBITDA and $60M in net income.

Strides Pharma P&L

In the most recent fiscal year, Strides Pharma reported revenue of $531M and EBITDA of $96M.

Strides Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Strides Pharma Stock Performance

Strides Pharma has current market cap of $996M, and enterprise value of $1B.

Strides Pharma's stock price is $10.80.

Strides Pharma Valuation Multiples

Strides Pharma trades at 2.2x EV/Revenue multiple, and 11.3x EV/EBITDA.

Strides Pharma Financial Valuation Multiples

As of April 19, 2026, Strides Pharma has market cap of $996M and EV of $1B.

Equity research analysts estimate Strides Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Strides Pharma has a P/E ratio of 16.7x.

Strides Pharma Margins & Growth Rates

Strides Pharma's revenue in the last 12 month grew by 17%.

Strides Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Strides Pharma's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Strides Pharma's rule of X is 58% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Strides Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Strides Pharma M&A Activity

Strides Pharma acquired XXX companies to date.

Last acquisition by Strides Pharma was on XXXXXXXX, XXXXX. Strides Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Strides Pharma Investment Activity

Strides Pharma invested in XXX companies to date.

Strides Pharma made its latest investment on XXXXXXXX, XXXXX. Strides Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).